The average P/S ratio for CLDX's competitors is 239.17, providing a benchmark for relative valuation. Celldex Therapeutics Inc Corp (CLDX) exhibits a P/S ratio of 372.11, which is 55.58% above the industry average. Given its robust revenue growth of 345.51%, this premium appears sustainable.